10-Q: IQVIA Holdings Q2 2026 Earnings: Revenue Growth Continues

IQVIA Holdings Inc. reported a solid second quarter for 2026, with revenues increasing by 8.7% year-over-year, driven by growth in both its Commercial Solutions and Research & Development Solutions segments.

Summary

• IQVIA Holdings Inc. reported total revenues of $4.368 billion for the second quarter of 2026, an increase of 8.7% compared to $4.017 billion in the same period of 2025.
• For the first six months of 2026, revenues grew by 8.6% to $8.519 billion from $7.846 billion in the prior year.
• Net income attributable to IQVIA Holdings Inc. was $256 million for the second quarter of 2026, a slight decrease from $266 million in Q2 2025, resulting in diluted EPS of $1.53.
• For the first six months of 2026, net income was $530 million, up from $515 million in the prior year, with diluted EPS of $3.14.
• The company's Commercial Solutions segment saw an 8.6% revenue increase in Q2 2026, while Research & Development Solutions segment revenue grew by 8.8%.
• The company repurchased $950 million of its common stock during the first six months of 2026.
• As of June 30, 2026, the company had $1.909 billion in cash and cash equivalents.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with solid revenue growth and segment profit increases, although a slight dip in net income and increased SG&A expenses warrant monitoring.

Positives

• Total revenues increased by 8.7% to $4.368 billion in Q2 2026, and by 8.6% to $8.519 billion for the first six months of 2026.
• Constant currency revenue growth was strong, with an 8.5% increase in Q2 and 7.3% for the first six months of 2026.
• Commercial Solutions segment profit increased by 10.6% to $419 million in Q2 2026.
• Research & Development Solutions segment profit increased by 11.2% to $526 million in Q2 2026.
• The company maintained compliance with its debt covenants.
• The company has a remaining authorization of $2.819 billion for stock repurchases.
• Net cash provided by operating activities increased by $165 million to $1.176 billion for the first six months of 2026.
• Cash used in investing activities decreased by $74 million for the first six months of 2026.

Negatives

• Net income attributable to IQVIA Holdings Inc. decreased slightly to $256 million in Q2 2026 from $266 million in Q2 2025.
• Diluted earnings per share decreased to $1.53 in Q2 2026 from $1.54 in Q2 2025.
• Cost of revenues, exclusive of depreciation and amortization, increased by 8.9% in Q2 2026, slightly outpacing revenue growth.
• Selling, general and administrative expenses increased by 12.8% in Q2 2026, a faster rate than revenue growth.
• Restructuring costs increased to $63 million in Q2 2026 from $32 million in Q2 2025.
• Interest expense increased to $197 million in Q2 2026 from $182 million in Q2 2025 due to higher outstanding debt balances.
• Cash used in financing activities increased significantly by $534 million for the first six months of 2026, primarily due to lower debt issuance proceeds.

Risks

• Business disruptions caused by natural disasters, pandemics, international conflict, or other unforeseen events.
• Loss or delays with large client contracts, or inability to enter into new contracts, as most contracts can be terminated on short notice.
• Failure to develop and market new services or enter new markets successfully.
• Imposition of restrictions on data use by suppliers or refusal to license data.
• Failure to comply with contractual, regulatory, or ethical requirements, including data protection and privacy laws.
• Security breaches or misuse of systems by the company or its outsourcing partners.
• Failure to meet productivity or business transformation objectives.
• Risks associated with operating globally, including currency fluctuations and legal compliance.

Future Outlook

The company expects to recognize revenues on approximately 30% of its $36.4 billion in remaining performance obligations over the next twelve months, and approximately 85% over the next five years. Restructuring actions are expected to continue throughout 2026 and into 2027. The company believes its available cash, future operating cash flows, and revolving credit facilities will enable it to fund its operating requirements, capital expenditures, and debt obligations for at least the next 12 months.

Management Comments

• The company is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry.
• We are a global leader in protecting individual patient privacy. We use a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes.
• Our insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.

Industry Context

StockSavvy.ai notes that IQVIA's performance aligns with broader trends in the life sciences industry, where demand for data analytics, clinical trial support, and real-world evidence is growing. The company's strategic segment realignment reflects an effort to better capture synergies and serve evolving client needs in a dynamic market.

Comparison to Industry Standards

• IQVIA's revenue growth of 8.6% for the first six months of 2026 is robust compared to the average growth rates seen in the broader healthcare IT and contract research organization (CRO) sectors, which have experienced moderate growth.
• The company's segment profit margins, particularly in Research & Development Solutions (approximately 20.3% for H1 2026), are competitive within the CRO industry, where margins can vary based on service mix and project complexity.
• While specific competitor data for Q2 2026 is not yet fully available, IQVIA's performance appears to be in line with or exceeding that of major CROs like PPD (now Thermo Fisher Scientific) and Syneos Health in terms of revenue expansion.

Legal Proceedings

• The company and its subsidiaries are involved in legal and tax proceedings incidental to their business. Management does not expect the resolution of these matters to have a material adverse effect on the company's financial statements, though individual unfavorable outcomes could have a material adverse effect for the period in which they are resolved.

Stakeholder Impact

• Shareholders: Continued revenue growth and segment profit increases are positive indicators. The ongoing stock repurchase program may support share value.
• Employees: Restructuring actions may lead to workforce adjustments, while growth in services supports employment.
• Clients: Continued provision of critical information, analytics, and research services supports client operations.
• Suppliers: Ongoing business operations imply continued engagement with suppliers.

Next Steps

• Continue to monitor global developments related to OECD Pillar Two legislation and assess potential impacts on the income tax provision.
• Continue restructuring actions throughout 2026 and into 2027 to align resources and reduce overcapacity.
• Evaluate new acquisition, expansion, and investment possibilities or other strategic growth opportunities.
• Continue to manage worldwide cash requirements and monitor available funds among subsidiaries.

Key Dates

Recommendation

The company demonstrates consistent revenue growth and operational strength, but a slight decrease in net income and increased operating expenses suggest a 'hold' recommendation. Investors should monitor SG&A expense control and the impact of ongoing restructuring.

Keywords

clinical research services, commercial insights, healthcare intelligence, life sciences, data analytics, pharmaceuticals, biotechnology, healthcare technology